Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 5/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GRN | P28799 | 1/20 | 0.30 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25846983 | 0.81 | CA2 (0.48) | MAPK1CA2CA1GRNSORT1 | |
| SCHEMBL16508843 | 0.78 | CA2 (0.55) | MAPK1CA2CA1USP2TSHR | |
| SCHEMBL1709280 | 0.75 | MAPK1 (0.41) | MAPK1GRNSORT1 | |
| SCHEMBL5372259 | 0.74 | — | — | |
| SCHEMBL1709290 | 0.72 | CYP2D6 (0.39) | MAPK1CA2CA1 | |
| SCHEMBL14374875 | 0.71 | MAPK1 (0.38) | MAPK1GRNSORT1 | |
| SCHEMBL14224894 | 0.68 | MAPK1 (0.35) | MAPK1GRNSORT1 | |
| SCHEMBL19183173 | 0.68 | MEN1 (0.46) | CA2CA1 | |
| SCHEMBL30022963 | 0.68 | MAPK1 (0.43) | MAPK1CA2GRNSORT1 | |
| SCHEMBL13632327 | 0.68 | MAPK1 (0.39) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | MAPK1 2497/4885CA2 4015/4885CA1 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.